
Opinion|Videos|September 25, 2024
Guiding Patients Through Third-Line mCRC Therapy Decisions
Medical experts discuss how to frame the conversation with patients about third-line metastatic colorectal cancer treatment selection, balancing efficacy, safety, and overall prognosis.
Advertisement
Episodes in this series

Video content above is prompted by the following:
When discussing treatment selection in the third-line setting for metastatic colorectal cancer, how do you frame this conversation with patients, balancing efficacy, safety, and overall prognosis?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
2
ICYMI: Highlights From SPD 2025
3
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
4
In CLL, New Therapies Offer Potential for Personalized Approaches
5










































